The Netupitant Palonosetron Market is attracting increasing attention as healthcare providers focus on improving the prevention of chemotherapy-induced nausea and vomiting (CINV). Growth Market Reports highlights that evolving cancer treatment protocols, increasing awareness of supportive care, and advances in combination therapies continue to shape market development across global healthcare systems.

As oncology care continues to evolve, the demand for effective antiemetic therapies is rising. Netupitant and palonosetron, used together as a fixed-dose combination, have become an important option for managing nausea and vomiting associated with highly and moderately emetogenic chemotherapy.

https://growthmarketreports.com/report/netupitant-palonosetron-market